Brief: Tenaya Therapeutics Enters Into Research Collaboration With Alnylam Pharmaceuticals To Identify And Validate Novel Genetic Targets For Cardiovascular Disease Therapeutics
05/03/2026 13:31
March 5 (Reuters) - Alnylam Pharmaceuticals Inc ALNY.O: TENAYA THERAPEUTICS ENTERS INTO RESEARCH COLLABORATION WITH ALNYLAM PHARMACEUTICALS TO IDENTIFY AND VALIDATE NOVEL GENETIC TARGETS FOR CARDIOVASCULAR DISEASE THERAPEUTICS TENAYA THERAPEUTICS INC - TO RECEIVE UP TO $10 MILLION UPFRONT AND UP TO $1.13 BILLION IN MILESTONE PAYMENTS TENAYA THERAPEUTICS INC - CO TO VALIDATE UP TO 15 GENE TARGETS UNDER AGREEMENT Source text: ID:nGNX2WBv5H Further company coverage: ALNY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027